SCHEMBL407408

SCHEMBL407408

N#CCC1COc2ccccc2O1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.51
ADRA1A P35348 2/20 0.51
HTT P42858 1/20 0.51
HTR1A P08908 1/20 0.51
DRD1 P21728 1/20 0.51
TBXA2R P21731 1/20 0.51
SLC6A2 P23975 1/20 0.51
DRD3 P35462 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1B P35368 1/20 0.51
SCN1A P35498 1/20 0.51
SCN2A Q99250 1/20 0.51
SCN3A Q9NY46 1/20 0.51
CA2 P00918 3/20 0.49
POLB P06746 1/20 0.49
ESR2 Q92731 1/20 0.49
MTNR1A P48039 1/20 0.49
ALOX5 P09917 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203262 0.83 HTT (0.56) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL2329045 0.82 HTT (0.55) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL11028792 0.80 HTT (0.54) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL11484814 0.79 ADRA2A (0.56) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL18727991 0.79 CA2 (0.48) HTTDRD3CA2HPGDSMN1; SMN2
SCHEMBL4006063 0.78 CA2 (0.34) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL11215832 0.76 CA2 (0.51) ADRA1AADRA1DADRA1BCA2HPGD
SCHEMBL568115 0.76 ADRA2A (0.60) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL8186813 0.76 ADRA2A (0.60) ADRA2AADRA1AHTTHTR1ADRD1
SCHEMBL10919900 0.76 CA2 (0.40) ADRA1AHTTADRA1DADRA1BCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768970-B1 SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2016-03-09 EP disclosed
US-8937096-B2 Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
US-8937096-B2 Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
US-8853263-B2 Co-therapy for the treatment of epilepsy and related disorders JANSSEN PHARMACEUTICA NV (BE) 2014-10-07 US disclosed
US-8853263-B2 Co-therapy for the treatment of epilepsy and related disorders JANSSEN PHARMACEUTICA NV (BE) 2014-10-07 US disclosed
EP-1968572-B1 USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION JANSSEN PHARMACEUTICA NV (BE) 2014-08-06 EP disclosed
EP-2276481-B1 USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY JANSSEN PHARMACEUTICA NV (BE) 2014-07-30 EP disclosed
US-8716231-B2 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain JANSSEN PHARMACEUTICA NV (BE) 2014-05-06 US disclosed
US-8716231-B2 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain JANSSEN PHARMACEUTICA NV (BE) 2014-05-06 US disclosed
US-8691867-B2 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction JANSSEN PHARMACEUTICA NV (BE) 2014-04-08 US disclosed
EP-0047531-A1 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them SYNTEX (U.S.A.) INC. (US) 1982-03-17 EP disclosed
US-4315021-A 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles SYNTEX (U.S.A.) INC. (US) 1982-02-09 US disclosed
EP-0004358-B1 N-OXACYCLYLALKYL PIPERIDINES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS CIBA-GEIGY AG (CH) 1982-01-06 EP disclosed
US-4302469-A 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants SYNTEX (U.S.A.) INC. (US) 1981-11-24 US disclosed
US-4301171-A 2-(1,4-Benzodioxan-2-ylalkyl)benzimidazoles useful as anti-depressants SYNTEX (U.S.A.) INC. (US) 1981-11-17 US disclosed
EP-0004358-A1 N-oxacyclylalkyl piperidines, process for their preparation, pharmaceutical compositions containing these compounds CIBA-GEIGY AG (CH) 1979-10-03 EP disclosed
US-4140781-A Analgesic and neuraleptic 2-piperidinoalkyl-1,4-benzodioxans CIBA-GEIGY CORPORATION (US) 1979-02-20 US disclosed
US-4129655-A Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans CIBA-GEIGY CORPORATION (US) 1978-12-12 US disclosed
US-4104396-A NEUROLEPTIC, ANALGESIC CIBA-GEIGY CORPORATION (US) 1978-08-01 US disclosed
US-4039676-A NEUROLEPTIC AGENTS CIBA-GEIGY CORPORATION (US) 1977-08-02 US disclosed